KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer

被引：0
|
作者：
Di Fiore, F. [1 ]
Le Pessot, F. [1 ]
Lamy, A. [1 ]
Charbonnier, F. [1 ]
Sabourin, J. [1 ]
Paillot, B. [1 ]
Frebourg, T. [1 ]
Michel, P. [1 ]
机构：
[1] Rouen Univ Hosp, INSERM, U 614, Rouen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10502
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients
    Yuriko Ito
    Yasuhide Yamada
    Kiyoshi Asada
    Toshikazu Ushijima
    Satoru Iwasa
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1391 - 1396
  • [32] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [33] EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients
    Ito, Yuriko
    Yamada, Yasuhide
    Asada, Kiyoshi
    Ushijima, Toshikazu
    Iwasa, Satoru
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (08) : 1391 - 1396
  • [34] Re: Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
    Brandi, Giovanni
    Biasco, Guido
    Tavolari, Simona
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (16) : 1278 - 1278
  • [35] EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer
    Finocchiaro, G.
    Cappuzzo, F.
    Janne, P. A.
    Bencardino, K.
    Carnaghi, C.
    Franklin, W. A.
    Roncalli, M.
    Crino, L.
    Santoro, A.
    Varella-Garcia, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells
    Nakadate, Yusuke
    Kodera, Yasuo
    Kitamura, Yuka
    Shirasawa, Senji
    Tachibana, Taro
    Tamura, Tomohide
    Koizumi, Fumiaki
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (09) : 2146 - 2155
  • [37] KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients
    Landi, L.
    Biagioni, F.
    Ludovini, V.
    Sacconi, A.
    D'Arcangelo, M.
    Destro, A.
    Blandino, G.
    Roncalli, M.
    Crino, L.
    Cappuzzo, F.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S417 - S417
  • [38] Kras mutations in colorectal cancer is a predictive factor of response and survival in patients treated with cetuximab
    Laurent-Puig, P.
    Livre, A.
    Boige, V
    Bachet, J.
    Ychou, M.
    Bouche, O.
    Pezet, D.
    Landi, B.
    Louvet, C.
    Andre, T.
    Ducreux, M.
    Rougier, P.
    Penault-Llroca, F.
    ANNALS OF ONCOLOGY, 2007, 18 : VII81 - VII81
  • [39] Frequency of KRAS/BRAF mutations as predictive markers for Cetuximab in Japanese colorectal cancer patients
    Yokota, T.
    Shibata, N.
    Ura, T.
    Takahari, D.
    Shitara, K.
    Muro, K.
    Yatabe, Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 351 - 351
  • [40] Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
    Qiu, Li-Xin
    Mao, Chen
    Zhang, Jian
    Zhu, Xiao-Dong
    Liao, Ru-Yan
    Xue, Kai
    Li, Jin
    Chen, Qing
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) : 2781 - 2787
12345